Flávia Saldanha Kubrusly

Flávia Saldanha Kubrusly

Auto-generated profile, based on publicly available information

Flávia Saldanha Kubrusly

Instituto Butantan, São Paulo, SP, Brazil

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Infection and Immunity
Verified
Journal Article
Closed access
PDF file
EVElaine C. Vicentin
Elaine C. Vicentin
KFKátia S. Françoso
Kátia S. Françoso
MRMariana V. Rocha
Mariana V. Rocha
DIDmitri Iourtov
Dmitri Iourtov
FSFernanda L. dos Santos
Fernanda L. dos Santos
ISIrene Soares
Irene Soares
In a recent vaccine trial performed with African children, immunization with a recombinant protein based on Plasmodium falciparum apical membrane antigen 1 (AMA-1) conferred a significant degree of strain-specific resistance against malaria. To contribute to the efforts of generating a vaccine against Plasmodium vivax malaria, we expressed the ectodomain of P. vivax AMA-1 (PvAMA-1) as a secreted soluble protein in the methylotrophic yeast Pichia pastoris . Recognized by a high percentage of sera from individuals infected by P. vivax , this recombinant protein was found to have maintained its antigenicity. The immunogenicity of this protein was evaluated in mice using immunization protocols that included homologous and heterologous prime-boost strategies with plasmid DNA and recombinant protein. We used the following formulations containing different adjuvants: aluminum salts (Alum), Bordetella pertussis monophosphoryl lipid A (MPLA), flagellin FliC from Salmonella enterica serovar Typhimurium, saponin Quil A, or incomplete Freund's adjuvant (IFA). The formulations containing the adjuvants Quil A or IFA elicited the highest IgG antibody titers. Significant antibody titers were also obtained using a formulation developed for human use containing MPLA or Alum plus MPLA. Recombinant PvAMA-1 produced under “conditions of good laboratory practice” provided a good yield, high purity, low endotoxin levels, and no microbial contaminants and reproduced the experimental immunizations. Most relevant for vaccine development was the fact that immunization with PvAMA-1 elicited invasion-inhibitory antibodies against different Asian isolates of P. vivax . Our results show that AMA-1 expressed in P. pastoris is a promising antigen for use in future preclinical and clinical studies.

15 September 2003 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
YWYong-Zheng Wu
Yong-Zheng Wu
SMSamir Medjane
Samir Medjane
SCSophie Chabot
Sophie Chabot
FKFlavia Saldanha Kubrusly
Flavia Saldanha Kubrusly
IRIsaias Raw
Isaias Raw
LTLhousseine Touqui
Lhousseine Touqui
We previously showed that surfactant inhibits the synthesis of type IIA secretory phospholipase A2 (sPLA2-IIA) by alveolar macrophages. These cells have been identified as the main source of this enzyme in an animal model of acute lung injury. The aim of the present study was to identify the surfactant components involved in the inhibition of sPLA2-IIA expression in alveolar macrophages and the signaling pathways that mediate this inhibition. Our results show that various surfactant preparations can inhibit sPLA2-IIA expression in endotoxin-stimulated alveolar macrophages. Both the surfactant protein (SP)-A and the surfactant phospholipid fraction inhibit this expression. The surfactant phospholipid dioleylphosphatidylglycerol (DOPG) abolishes sPLA2-IIA expression, whereas dipalmitoylphosphatidylcholine does not. Chromatographic analysis and confocal microscopy revealed that phosphatidylglycerol was rapidly incorporated and metabolized by alveolar macrophages and that its metabolites accumulate in the cytosol. Nuclear factor-κB (NF-κB) modulates sPLA2-IIA expression in endotoxin-activated alveolar macrophages, and surfactant preparations, surfactant phospholipid fraction, SP-A, and DOPG indeed suppressed NF-κB activation. In summary, our results show that SP-A and DOPG play a role in the surfactant-mediated inhibition of sPLA2-IIA expression in alveolar macrophages and that this inhibition occurs via a downregulation of NF-κB activation.

1 January 2007 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
CPC.T. Perciani
C.T. Perciani
PPP.S. Peixoto
P.S. Peixoto
WDW.O. Dias
W.O. Dias
FKF.S. Kubrusly
F.S. Kubrusly
MTM.M. Tanizaki
M.M. Tanizaki
The methods currently used to determine the immunoglobulin avidity index (AI) require the choice of a reference point in the ELISA titration curve. Since both curves, with and without denaturating reagents, seldom run in parallel, the AI value becomes highly dependent on this reference. The new method for AI calculation presented here takes into account the whole data of the ELISA titration curve in which the final numerical AI is the average of each point. J. Clin. Lab. Anal. 21:201–206, 2007.

1 July 2004 in Infection and Immunity
Verified
Journal Article
Closed access
PDF file
RMRick Malley
Rick Malley
SMSarah C. Morse
Sarah C. Morse
LLLuciana C. C. Leite
Luciana C. C. Leite
AAAna Paula Mattos Areas
Ana Paula Mattos Areas
PHPaulo Lee Ho
Paulo Lee Ho
PAPorter Anderson
Porter Anderson
Intranasal challenge of C57BL/6 mice with Streptococcus pneumoniae serotypes 6B, 14, and 23F produced colonization of the middle ear and NP. Intranasal vaccination with ethanol-killed nonencapsulated cells with adjuvant protected both sites. Of four nontoxic adjuvants tested, the cholera toxin B subunit was most effective and least nonspecifically protective.

1 February 2013 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
WDWaldely Dias
Waldely Dias
AAArno A.J. van der Ark
Arno A.J. van der Ark
MSMaria Aparecida Sakauchi
Maria Aparecida Sakauchi
FKFlávia Saldanha Kubrusly
Flávia Saldanha Kubrusly
APAna Fabíola R.O. Prestes
Ana Fabíola R.O. Prestes
IRIsaias Raw
Isaias Raw
An improved whole cell pertussis vaccine, designated as Plow, which is low in endotoxicity due to a chemical extraction of lipo-oligosaccharide (LOS) from the outer membrane, was evaluated for safe...

8 December 2009 in Reproduction, Fertility and Development
Verified
Journal Article
Closed access
PDF file
FMFlávio Vieira Meirelles
Flávio Vieira Meirelles
EJEduardo Harry Birgel Junior
Eduardo Harry Birgel Junior
FPFelipe Perecin
Felipe Perecin
MBMarcelo Bertolini
Marcelo Bertolini
ATAnneliese S. Traldi
Anneliese S. Traldi
LSLiege C. G. Silva
Liege C. G. Silva
The production of a healthy cloned calf is dependent on a multitude of successful steps, including reprogramming mediated by the oocyte, the development of a functional placenta, adequate maternal–fetal interaction, the establishment of a physiological metabolic setting and the formation of a complete set of well-differentiated cells that will eventually result in well-characterised and fully competent tissues and organs. Although the efficiency of nuclear transfer has improved significantly since the first report of a somatic cell nuclear transfer-derived animal, there are many descriptions of anomalies concerning cloned calves leading to high perinatal morbidity and mortality. The present article discusses some our experience regarding perinatal and neonatal procedures for cloned Zebu cattle (B. indicus) that has led to improved survival rates in Nellore cloned calves following the application of such ‘labour-intensive technology’.